Xenetic Biosciences IncNASDAQ:XBIONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4004
- TODAY'S CHANGE (%)0.0084 (2.1429%)
- Bid / Lots0.2803/ 30
- Ask / Lots0.5400/ 20
- Open / Previous Close0.3929 / 0.3920
- Day Range
- 52 Week Range
- Volume68,148
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XBIO |
|---|---|---|
| 09:32 ET | 1067 | 0.3929 |
| 11:31 ET | 5000 | 0.3951 |
| 12:14 ET | 8600 | 0.43 |
| 01:03 ET | 5174 | 0.43 |
| 01:15 ET | 23091 | 0.4125 |
| 01:19 ET | 23429 | 0.422 |
| 01:30 ET | 134 | 0.3971 |
| 01:33 ET | 100 | 0.413 |
| 03:16 ET | 200 | 0.4019 |
| 03:50 ET | 800 | 0.4004 |
Mar 23, 2023
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update, from 7:35AM ET on Thursday Mar 23, 2023 by Accesswire
7:35AM ET on Thursday Mar 23, 2023 by Accesswire
Mar 16, 2023
JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences, from 11:01AM ET on Thursday Mar 16, 2023 by Accesswire
11:01AM ET on Thursday Mar 16, 2023 by AccesswireXenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event, from 8:07AM ET on Thursday Mar 16, 2023 by Accesswire
8:07AM ET on Thursday Mar 16, 2023 by Accesswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenetic Biosciences Inc | 5.9M | -0.8x | --- |
Timber Pharmaceuticals Inc | 6.2M | -0.1x | --- |
Soligenix Inc | 5.3M | -0.4x | --- |
InMed Pharmaceuticals Inc | 4.4M | -0.1x | --- |
Nascent Biotech Inc | 7.3M | -2.4x | --- |
Vyant Bio Inc | 3.8M | 0.1x | --- |
Company Information
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on developing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell non-Hodgkin lymphomas. In addition, the Company is leveraging its drug delivery platform, PolyXen, by partnering with biotechnology and pharmaceutical companies. Its product pipeline includes XCART and ErepoXen, or polysialylated erythropoietin (PSA-EPO). PSA-EPO uses its PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It is designed to reduce the dosing frequency by extending the circulating half-life of therapeutic in the body.
Contact Information
- Headquarters
- 945 Concord St.FRAMINGHAM, MA, United States 01701
- Phone
- 781-778-7720
- Fax
- ---
Executives
- Independent Chairman of the Board
- Adam Logal
- Chief Executive Officer, Director
- Jeffrey Eisenberg
- Chief Financial Officer, Corporate Secretary
- James Parslow
- Chief Scientific Officer
- Curtis Lockshin
- Independent Director
- Grigory Borisenko
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9M |
|---|---|
Revenue (TTM) | $1.6M |
Shares Outstanding | 15.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.84 |
EPS | $-0.50 |
Book Value | $1.37 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 3.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -452.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
